It's not junk food causing the problem here
As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide activates three metabolic pathways where semaglutide activates one and tirzepatide activates two
Lipid Panel Changes Retatrutide consistently improves lipid profiles: Triglycerides: Significant reductions, driven by reduced hepatic VLDL production and improved fat metabolism LDL cholesterol: Modest reductions observed HDL cholesterol: Tends to be preserved or mildly increased Non-HDL cholesterol: Meaningful improvements across studies These lipid changes are clinically relevant and contribute to the overall cardiovascular risk reduction profile
It may take time to see changes, especially if a washout period is needed. Comparing weight loss results Tirzepatide shows significantly better weight loss results in clinical studies: In a large study of over 18,000 patients, those taking tirzepatide lost about 15.3% of their body weight in one year, compared to 8.3% with semaglutide
MT1 and MT2 melatonin receptors: a therapeutic perspective